# Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

> **NCT05146219** · PHASE2 · COMPLETED · sponsor: **TYK Medicines, Inc** · enrollment: 29 (actual)

## Conditions studied

- NSCLC
- EGFR Activating Mutation
- Brain Metastases
- Leptomeningeal Metastasis

## Interventions

- **DRUG:** TY-9591 Tablets

## Key facts

- **NCT ID:** NCT05146219
- **Lead sponsor:** TYK Medicines, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-02
- **Primary completion:** 2024-03-21
- **Final completion:** 2024-11-13
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2024-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05146219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05146219, "Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05146219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*